Rein Therapeutics Inc. RNTX
0.34 USD -0.03 (-8.38%)
Regular-session close
0.39 +0.05 +15.76%
After hours · Nov 20, 6:46 PM ET
0.3352 Day range 0.3899
0.284 52-week range 2.10
- YTD
- -70.96%
- 1 year
- -75.59%
5D -0.1629 (-29.61%)
- Market cap
- 29.06M
- EPS (ttm)
- -1.51
- YTD return
- -70.96%
- 1-year return
- -75.59%
- Volume
- 668.75K
- Avg volume
- 585.30K
- Open
- 0.3575
- Previous close
- 0.3677
- Day's range
- 0.3352 – 0.3899
- 52-week range
- 0.284 – 2.10
Fundamental scorecard
7 of 25 checks passed on RNTX’s reported financials
7of 25 checks passed
- Value 1 of 5
- Growth 1 of 5
- Profitability 0 of 5
- Financial health 5 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Financials — quick view
RNTX Revenue — quarterly 0
RNTX Net income — quarterly -5.54M
RNTX EPS — quarterly -0.06
News
HC Wainwright & Co. Reiterates Buy on Rein Therapeutics, Maintains $8 Price Target
12 Health Care Stocks Moving In Monday's Intraday Session Rein Therapeutics Reports Preliminary 12-Week Blinded Phase 2 RENEW Data For LTI-03 In IPF Patients; Study Achieves 75% Enrollment, With 90 Patients Randomized To Date; On Track To Report Topline Data In 2027
Rein Therapeutics Announces Preliminary Blinded Phase 2 RENEW Data Showing Encouraging Lung Function Trends in Patients with Idiopathic Pulmonary Fibrosis and Reports Third Quarter 2026 Financial Results Rein Therapeutics Q3 EPS $(0.06) Beats $(0.10) Estimate
Your note
Sign in to keep a note on RNTX — it syncs with the Stock Master app.
